Ischemic neuronal injury is associated with several life-and vision-threatening diseases. Neuroprotection is essential in the treatment of these diseases. Here, we identified and characterized a novel peptide, FK18, from basic fibroblast growth factor (bFGF). We further assessed the neuroprotective effects of this peptide and its potential mechanisms using the in vitro oxygeneglucose deprivation (OGD) model in SH-SY5Y cells and the in vivo retinal ischemia-reperfusion (I/R) injury model to mimic ischemic neuronal injury. Our results suggested that FK18 significantly increased the viability of and attenuated the apoptosis of SH-SY5Y cells. It also markedly alleviated I/R-induced retinal neuronal apoptosis, damage to retinal ganglion cells (RGCs), and morphological and functional damage to the retina. Moreover, FK18 increased Akt phosphorylation under both normoxic and OGD conditions, attenuated mitochondrial translocation of the proapoptotic protein Bad, up-regulated the expression of Bcl-2/Bax, and inhibited the release of cytochrome c from the mitochondria into the cytoplasm. These results suggested that FK18 is a novel neuroprotective agent that may serve as a prototype for neuroprotective drug development.
Introduction
Cerebral ischemic injury, which occurs when the cerebral blood supply is cut off, resulting in oxygen and glucose deprivation in brain tissues, is one of the leading causes of death and long-term disability worldwide (Mozaffarian et al., 2016) . As part of the central nervous system, the visual system, including retinal ganglion cells (RGCs) and other neurons, is also susceptible to ischemic injury. Retinal ischemia plays important roles in the pathogenesis of several vision-threatening diseases, including retinal artery occlusion, diabetic retinopathy, glaucoma, and optic neuropathy (Osborne et al., 2004) . These diseases are major causes of blindness worldwide and usually result in vision loss due to irreversible damage to retinal neurons.
Neuroprotection is necessary in the treatment of ischemic neuronal injury to optimize patient outcome, in addition to therapeutic strategies primarily directed at the vasculature to promote prompt restoration of the blood supply or to maintain circulatory patency (Ginsberg, 2008; Osborne et al., 2004) . At present, chemicals, such as calcium channel blockers, glutamate antagonists, and antioxidant/radical scavenging agents, are primarily used to provide pharmacological neuroprotection (Gwag et al., 2007; Maniskas et al., 2016; Sakata et al., 2010; Sun et al., 2015; Wang et al., 2016; Weng and Kriz, 2007) . Recombinant protein therapeutics is another popular approach for neuroprotection, and it involves the use of neurotrophic factors, growth factors, erythropoietin (EPO), etc. (Jiang et al., 2011; Junk et al., 2002; Larpthaveesarp et al., 2016; Li and Stephenson, 2002; Tabakman et al., 2005; Zhao et al., 2016) . Nevertheless, the drawbacks of small-molecule chemicals (e.g. low target specificity and unexpected side effects) and protein Abbreviations: bFGF, basic fibroblast growth factor; OGD, oxygeneglucose deprivation; I/R, ischemia-reperfusion; PBS, phosphate-buffered saline; IOP, intraocular pressure; RGCs, retinal ganglion cells; IPL, inner plexiform layer (IPL); INL, inner nuclear layer; ORL, outer retinal layer; GCL, ganglion cell layer; TUNEL, TdTMediated dUTP FG, ERG, Electroretinogram; PI3K, therapeutics (e.g. poor bioavailability, low membrane permeability, and a long manufacturing cycle) impede their effective application (Craik et al., 2013) . Therefore, small-molecule bioactive peptides that combine the advantages of chemical and protein therapeutics but overcome their disadvantages will likely become a new hot area of investigation for researchers.
To this end, we identified a novel 18-amino acid peptide, FK18, from basic fibroblast growth factor (bFGF), one of the 22 members of the FGF family that share an internal core region of~120 amino acids, with~30%e60% identical residues (Itoh and Ornitz, 2004) . Then, we assessed its neuroprotective effects and potential mechanisms using the well-established in vitro oxygeneglucose deprivation (OGD) model in neuronal SH-SY5Y cells and the highly reproducible in vivo retinal ischemia-reperfusion (I/R) injury model to mimic ischemic insult to neurons.
Materials and methods

Preparation of peptides
A sequence segment of 18 amino acids (FFFERLESNNYNTYRSRK, molecular weight: 2371.6 Da) was selected based on combined analysis of the active binding domain of bFGF (the loop between b10-b11 and the regions involving b8-b9) and the conserved amino acid sequence among members of the FGF family and among different species (Baird et al., 1988; Eriksson et al., 1991; Ornitz, 2004, 2008; Plotnikov et al., 1999; Zhu et al., 1991) . The structure of the peptide is presented in Fig. 1 . To determine whether the neuroprotective effect of FK18 is sequence dependent, a scrambled peptide (SCpep) was simultaneously synthesized and used as a negative control in the following in vitro and in vivo experiments.
FK18 and SCpep were synthesized by China Peptides Co., Ltd. (Shanghai, PR China) with a high-efficiency solid-phase method utilizing an automatic peptide synthesizer (Symphony; Protein Technologies, Tucson, AZ). Characterization of the purified peptides was performed by analytical high-performance liquid chromatography (HPLC, analytical; Shimadzu, Kyoto, Japan) and mass spectrometry (MS, Finnigan TSQ 7000; Thermo, Waltham, MA) after synthesis and purification, and all peptides were freeze-dried and stored at À20 C until use.
Stability assay of peptides in aqueous solutions
The stability of peptides in various aqueous solutions was investigated, as described in previous study (Staes et al., 2010; Xu et al., 2010) . Lyophilized FK18 and SCpep were dissolved in water or in buffer at a concentration of 250 mg/ml. Buffers included: 1) sodium citrate buffer solution pH 4; 2) sodium citrate buffer solution pH 6; 3) Hanks balanced salt solution (HBSS) PH 7.4; 4) phosphate buffer saline (PBS) pH 7.4; and 5) BSS PLUS™ sterile intraocular irrigating solution (Alcon, Inc.; Hünenberg, Switzerland). BSS PLUS™ is an intraocular irrigating solution for use during all intraocular surgical procedures (used to imitate the intraocular condition). The peptide solutions were incubated at 4 C or 37 C for 4, 24, or 48 h, then stored at À80 C. The solutions without incubation and immediately frozen at À80 C were served as controls. The stability of peptides was evaluated by HPLC. Samples were thawed at room temperature for 5 min before testing.
Cell culture and treatment
The human neuroblastoma cell line SH-SY5Y, which has similar morphological, neurochemical and electrophysiological properties to neurons, was purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences. Cells were maintained in DMED/F-12 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Gibco, Carlsbad, CA) and were kept in a humidified atmosphere with 5% carbon dioxide at 37 C. The SH-SY5Y cells were passaged by trypsinization every 5e6 d. The cells were subjected to OGD as previously reported (Marutani et al., 2012) . Briefly, they were washed twice with phosphate-buffered saline (PBS), and the medium was replaced with glucose-free RPMI 1640 containing L-glutamine (Gibco, Carlsbad, CA) that had been deoxygenated with an anaerobic gas mixture (95% N2e5% CO2) for 30 min before use. The cells were then placed in a hypoxia chamber, flushed with the anaerobic gas mixture (95% N2e5% CO2) and incubated at 37 C. After different lengths of time (1e12 h), the medium was replaced with DMEM/F-12, and the cells were incubated for 12 h in 95% air/5% CO2 in a humidified incubator. Different concentrations of FK18 (0.1, 1, 10, 50, and 100 mg/ml), SCpep (10 mg/ ml) and recombinant human bFGF (100 ng/ml, R&D) were each added to separate aliquots of cells 2 h prior to the induction of OGD. FK18, SCpep and bFGF were dissolved in PBS. For investigation of the effect of FK18 on Akt phosphorylation, a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002 (20 mM, Beyotime Institute of Biotechnology, Shanghai, China), was added 2 h prior to the addition of FK18. The control cells were subjected to the same experimental procedures with vehicle only and without exposure to the glucose-free medium or anoxia.
Animals
Adult male Wistar rats weighing 180e200 g were purchased from Shanghai Laboratory Animal Center, Chinese Academy Sciences and used for all the experiments. All animals were fed with a standard diet ad libitum and maintained under a 12-h light/12-h dark photoperiod. All procedures involving animals conformed to the ARVO statement for the Use of Animals in Ophthalmic and 1BAS). bFGF is a single-stranded 146-amino acid polypeptide that adopts a b-trefoil structure containing four-stranded b-sheets arranged in a triangular array. The sequence of FK18 is presented as a stick structure in magenta, and the remainder of bFGF is presented in cartoon form in wheat. This image was created with a PyMOL Molecular Graphic system (Delano Scientific). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Vision Research. All types of surgery and manipulation were performed in Shanghai Key Laboratory of Fundus Disease. The number of animals used for morphological and functional analysis was n ¼ 6 for each intervention and group.
Retinal ischemia
Before initiation of the experiment, the rats were deeply anesthetized by intraperitoneal injection of 10% (w/v) chloral hydrate. One drop of 0.4% oxybuprocaine hydrochloride was administered for corneal anesthesia, and one drop of 5% tropicamide was applied for pupil dilation. Thirty minutes prior to the onset of retinal ischemia, the rats were randomized to receive one of the following treatments using a computer-generated list: 5 mg/eye FK18, 20 mg/ eye FK18, 20 mg/eye SCpep, 20 mg/eye bFGF or normal PBS. These injections were performed intravitreally by puncturing the eye with a 30-gauge needle at the corneal-scleral junction. For the induction of retinal ischemia, the anterior chamber was cannulated with a 30-gauge needle connected to a container of sterile saline. The container was elevated to raise the intraocular pressure (IOP) above the systolic blood pressure (150 mmHg) for 60 min. Retinal ischemia was confirmed by observing whitening of the iris and loss of the red reflex of the retina. Then, the pressure was returned to normal, and the eye was examined to ensure that retinal blood flow had been reestablished. Rats with lens injuries and vitreous hemorrhages were excluded from the investigation. A sham procedure was performed on control eyes without elevation of the container. Body temperature was maintained at 37 C with a heating blanket from the time of the induction of anesthesia until the animals had recovered from the anesthesia. The injections were repeated every 2 days for one week. For the evaluation of the effect of FK18 on Akt phosphorylation in vivo, 20 mg/eye FK18 was injected intravitreally without the induction of retinal ischemia.
Cell viability assay
Cell viability was quantitatively evaluated at 1 h, 3 h, 6 h, and 12 h of OGD and at 12 h of re-oxygenation with and without pretreatment with different concentrations of FK18, SCpep or bFGF using an MTS kit (Promega, Madison, WI, USA). Briefly, 20 ml of an MTS solution was added to each well of a 96-well microtiter plate, and the plate was incubated for 2 h at 37 C. Absorbance was measured at 490 nm using a microtiter plate reader. Cell viability was expressed as a percentage of the optical density measured in the control group.
Annexin V staining and flow cytometry
The percentage of apoptotic cells following OGD insult was determined by flow cytometry using an Annexin V-FITC/PI Detection Kit (BD Pharmingen, San Diego, CA, USA), according to the manufacturer's instructions. Briefly, cells were digested with 0.05% trypsin for 5 min, and neurons were collected by centrifugation (1000Âg for 5 min). The pellets were washed twice with cold PBS and then resuspended in binding buffer at a concentration of 1 Â 10 6 cells/ml. A 100 ml volume of the cell suspension (1 Â 10 5 cells) was then transferred to a 5 ml culture tube with the addition of 5 ml FITC Annexin V and 5 ml PI. After incubation of the cells in the dark at room temperature for 15 min, they were analyzed by flow cytometry (FACS Caliber, Becton Dickinson, Heidelberg, Germany).
Histological examination
7The rats were euthanized on day 7 of reperfusion for morphometric analysis. The eyes were enucleated and fixed for 24 h at 4 C. After fixation, the anterior segment was removed from each eye. The posterior eyecup was dehydrated and embedded in paraffin. Retinal cross sections (5 mm thick) were then cut and stained with hematoxylin and eosin (Sigma, MO, USA). The sections were photographed and measured at approximately 2e3 disc diameters from the optic nerve using a microscope (Olympus BX53; Olympus, Tokyo, Japan). The thicknesses of the inner plexiform layer (IPL), inner nuclear layer (INL), and outer retinal layer (ORL, the part of the retina from the outer plexiform layer to the retinal pigment epithelial cell layer) were measured. The number of cells in the ganglion cell layer (GCL) was determined by cells counts over a distance scale of 200 mm. In each eye, the retinal thickness and cell number were calculated as the mean values of at least three measurements in adjacent sections. The thickness of retinal layers and the number of cells were determined in blinded fashion by an independent scientist.
TdT-mediated dUTP Nick-end labeling (TUNEL) assay
For the in vitro experiments, after OGD insult, SH-SY5Y cells were fixed with 4% paraformaldehyde (PFA) in PBS for 25 min at 4 C, and they were then permeabilized with 0.2% Triton X-100 for 5 min. For the in vivo experiments, at 24 h after reperfusion (n ¼ 6 in each group), paraffin-embedded retinal tissue sections, prepared as mentioned above, were deparaffinized, rehydrated, fixed with 4% PFA for 15 min at 4 C, and then subjected to enzymatic digestion with 20 mg/ml proteinase K for 8e10 min at room temperature.
Induction of apoptosis was examined by TUNEL assay using a DeadEnd™ Fluorometric TUNEL System (Promega, Madison, WI, USA) in both the in vitro and in vivo experiments, according to the manufacturer's instructions. Nuclei were imaged by counterstaining with 4 0 ,6-diamidino-2-phenylindole (DAPI) in vitro and phenylindole (PI) in vivo. TUNEL-positive cells were examined using a laser scanning confocal microscope (Zeiss LSM 510, Carl Zeiss, Germany) in vitro in six random fields (at least 100 DAPI-positive cells per field) for each experimental group. The level of apoptosis was expressed as the ratio of the number of TUNELpositive cells to that of DAPI-positive cells. The numbers of TUNEL-positive cells in the GCL and INL were counted in vivo in six microscopic fields of the retinal sections, which were each 167 mm in length, including three on either side of the optic nerve head, beginning at approximately 170 mm from the optic head. TUNELpositive cells were counted in blinded fashion by an independent scientist, both in vitro and in vivo. The results were expressed as the linear cell density (cells/mm) (Kaneda et al., 1999) . In each eye, the numbers of TUNEL-positive cells in the GCL and INL were calculated as the mean values of at least three measurements in adjacent sections.
Retrograde labeling and quantification of RGCs
The rats were deeply anesthetized by intraperitoneal injection of 10% (w/v) chloral hydrate. Then, the rat heads were fixed in a stereotactic apparatus (Stoelting Kiel, Germany), and the skin overlying the cranium of each rat was incised. Fluoro-Gold (FG; Biotium, Hayward, CA, USA) was injected (2 mL of 4% FG in distilled H 2 O) into the superior colliculus (SC) on each side using a microsyringe. Seven days after retinal ischemia, the animals were euthanized, and the eyes were enucleated. After removal of the vitreous bodies, the eyes were fixed with 4% PFA for 1 h. The whole retinas were then carefully dissected, divided into four radial cuts and mounted with the vitreous side up on a microscope slide. The retinas were examined in a blinded fashion by an independent scientist, using an Olympus BX53 fluorescence microscope (Olympus, Tokyo, Japan) with UV excitation (excitation filter, 350e400 nm; barrier filter, 515 nm) and a digital imaging system. For quantification of RGCs, each retina was divided into quadrants (superior, inferior, nasal, and temporal). The quadrants were further divided into central (0.8e1.2 mm from the optic disc), middle (1.8e2.2 mm from the optic disc), and peripheral regions (0.8e1.2 mm from the retinal border). Two standard square areas (200 Â 200 mm 2 ) were counted in each region. The density of RGCs in each group of rats was expressed as the number of labeled RGCs/ mm 2 of the counted retinal area (Chen et al., 2015b) .
Electroretinogram (ERG)
The ERG was performed at 7 d after retinal ischemia/reperfusion injury with a Ganzfeld system (RetiPort, Roland Consult, Brandenburg, Germany) and the experimenter was blind to group assignment. Rats were dark-adapted for 30 min and then anesthetized with an intraperitoneal injection of 10% (w/v) chloral hydrate (n ¼ 6 in each group). One drop of 0.4% oxybuprocaine hydrochloride was administered for corneal anesthesia, and one drop of 5% tropicamide was applied for pupil dilation. A silver wire electrode was placed in contact with the cornea, and a reference electrode was placed onto one ear; a ground electrode was placed in the tail. All procedures were performed in dim red light, and the rats were kept warm during the procedure until they had completely recovered from anesthesia. The responses to a light flash (3.0 cd s/m 2 ) from a photic stimulator were amplified, and the preamplifier bandwidth was set at 0.3e300 Hz. The amplitude of the a-wave was measured from the baseline to the maximum a-wave trough, and the b-wave was measured from the maximum a-wave trough to the maximum b-wave peak. The a-or b-wave relative ratio was defined as the aor b-wave amplitude of the right eye/the a-or b-wave amplitude of the left eye, respectively.
Protein extraction
Cells were lysed in RIPA lysis buffer containing PMSF and phosphatase inhibitor (v/v ¼ 98:1:1). The lysates were centrifuged at 15,000 Â g for 15 min at 4 C, and the supernatants were collected. The amount of protein in each lysate was determined using a BCA protein assay kit (Beyotime Institute of Biotechnology, Shanghai, China).
To measure cytochrome c concentrations, the mitochondrial fraction was isolated from the cytosolic fraction using a Mitochondria/Cytosol Fractionation Kit (Biovision, Mountain View, CA, USA) according to the manufacturer's instructions. Briefly, cells were harvested, washed with ice-cold PBS, resuspended in Cytosol Extraction Buffer Mix containing DTT and protease inhibitors, and Dounce-homogenized. The homogenate was centrifuged at 700 Â g for 10 min at 4 C to pellet nuclei and unbroken cells, and then the supernatant was transferred to a clean Eppendorf tube. Next, the supernatant was centrifuged at 10,000 Â g for 30 min at 4 C, and the resulting supernatant was collected as the cytosolic fraction.
The pellet was resuspended in 100 ml Mitochondrial Extraction Buffer Mix containing DTT and protease inhibitors and saved as the mitochondrial fraction.
Western blotting
Equal amounts of protein were electrophoresed in either 10% or 12% SDS-polyacrylamide gels and transferred onto polyvinylidene difluoride (PVDF) membranes. After the blocking of nonspecific binding with 5% nonfat milk for 1 h at 37 C, the membranes were incubated with a diluted primary antibody against phospho-fibroblast growth factor 1 (p-FGFR1) (1:1000, Cell Signaling Technology, Boston, MA, USA), FGFR1 (1:1000, Cell Signaling Technology, Boston, MA, USA), phospho-Akt (1:1000, Cell Signaling Technology, Boston, MA, USA), Akt (1:1000, Cell Signaling Technology, Boston, MA, USA), cytochrome c (1:1000, Cell Signaling Technology, Boston, MA, USA), p-Bad (1:1000, Cell Signaling Technology, Boston, MA, USA), Bcl-2 (1:1000, Cell Signaling Technology, Boston, MA, USA), Bax (1:1000, Cell Signaling Technology, Boston, MA, USA), Bcl-xL (1:1000, Cell Signaling Technology, Boston, MA, USA), cleaved caspase-9 (1:1000, Cell Signaling Technology, Boston, MA, USA), cleaved caspase-3 (1:1000, Sigma, MO, USA), COX-IV (1:1000, Cell Signaling Technology, Boston, MA, USA), b-actin (1:1000, Beyotime Institute of Biotechnology, Shanghai, China), or GAPDH (1:1000, Cell Signaling Technology, Boston, MA, USA) overnight at 4 C. Then, a secondary antibody (horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (1:10,000) (Jackson ImmunoResearch Laboratories Inc., West Grove, PA)) was applied for 2 h at room temperature. Bands were visualized using an enhanced chemiluminescence detection system (Millipore, Molsheim, France), and band densities were quantified using Adobe Photoshop software (Adobe, CA, USA). The expression levels of p-Bad, Bcl-2, Bax and Bcl-xL were normalized to that of GAPDH, the expression levels of caspase-3 and caspase-9 were normalized to that of full length caspase-3 and caspase-9, the p-FGFR level was expressed as a ratio of the level of p-FGFR1 to that of total FGFR1, and the pAkt level was expressed as a ratio of the level of p-Akt to that of total Akt. The expression of cytochrome c in cytoplasm was normalized to that of b-actin, while its expression in mitochondria was normalized to that of CoxIV.
Safety evaluation
The potential toxicity of FK18 was evaluated in vitro using SH-SY5Y cells and in vivo by intravitreal injection. SH-SY5Y cells were incubated with different concentrations (0.1e100 mg/ml) of FK18 for 24 h, and MTS assay was then performed to assess cell viability, as mentioned above. The eyes of the rats that received 20 mg of FK18 intravitreally were examined by biomicroscopy and ERG on the first and 7th day and were then enucleated for histological and transmission electron microscopy analyses.
Statistical analysis
The data are expressed as the mean ± SD of at least three independent experiments. Statistical analyses were performed by one-way ANOVA with Turkey's HSD or Dunnett's T3 post hoc test using IBM SPSS statistics version 24.0 (IBM Co., Armonk, NY, USA). Nonparametric data were analyzed using the Krustal-Wallis test. A p-value < 0.05 was considered statistically significant.
Results
Stability of FK18 and SCpep
The stability of FK18 and SCpep were analyzed as a percentage of the purity of control solutions. The two peptides have relatively good stability in water, sodium citrate solution buffer (pH 4), PBS, HBSS and sterile intraocular irrigating solution under the temperature of 4 C and 37 C for 4 h, 24 h and 48 h. Peptides dissolved in sodium citrate buffer solution (pH 6) were less stable with degeneration happened after incubation for 24e48 h. However, the degeneration only happened in small part of the total peptide content, and more than 97% still existed after 48 h. Details are shown in Table 1 .
FK18 improved cell viability in SH-SY5Y cells after OGD injury
SH-SY5Y cells were subjected to OGD for 1 h, 3 h, 6 h or 12 h, followed by re-oxygenation for 12 h. MTS assay showed that cell viability gradually decreased with increasing OGD time. The survival rates were 84.50± 1.75%, 60.10± 3.00%, 48.16± 1.61% and 31.52± 1.58% after 1 h, 3 h, 6 h and 12 h of OGD followed by reoxygenation, respectively (Fig. 2 A) . The insult of 6 h of OGD followed by 12 h of re-oxygenation, with a decrease in cell viability of 48%, was chosen in the present study.
Pretreatment with FK18 dramatically increased cell viability in both a dose-dependent and sequence-dependent manner, whereas
SCpep had no such effect. The peak effect was observed with 10 mg/ ml FK18, with an increase in cell viability from 46.88± 2.34% to 59.12± 2.20% (p < 0.01) after OGD insult (Fig. 2 B) . Further increasing the concentration resulted in a slightly decrease in cell viability; thus, we selected the FK18 concentration of 10 mg/ml to examine its protective effects in the following assays.
FK18 protected SH-SY5Y cells against OGD-induced apoptosis
The protective capacity of FK18 against OGD-induced apoptosis was assessed. The flow cytometry results demonstrated that pretreatment with FK18 reduced cell apoptosis from 30.26± 2.22% to 24.78± 1.43% (p < 0.01) after OGD injury (Fig. 3 A and C) . TUNEL assay was also conducted to visualize cell apoptosis. The percentage of TUNEL-positive cells increased significantly from 7.83± 1.58% to 24.10± 1.69% after OGD injury, while it decreased to 17.58± 1.39% following application of FK18 (Fig. 3 B and D) . However, SCpep pretreatment did not alleviate the cell apoptosis induced by OGD injury.
Intravitreal administration of FK18 has neuroprotective effects after I/R
To examine the neuroprotective effects of FK18 against I/Rinduced injury of the rat retina, we first evaluated the morphological changes at 7 d after I/R by hematoxylin and eosin staining (Fig. 4 A, B and C) . In the I/R-plus-vehicle group, the overall retinal thickness was significantly decreased. Although the ORL, including the photoreceptor layer and outer nuclear layer, exhibited mild thinning, the retinal degeneration was primarily due to significant collapse of the IPL and loss of the cell bodies in the INL, the thicknesses of which were decreased by 56.5% and 38.2%, respectively. I/ R injury also resulted in 63.1% cell loss from the GCL. By contrast, the IPL, INL and ORL thicknesses and GCL density in the I/R-plus-FK18 group were significantly and dose-dependently increased compared with those in the vehicle control group, with peak effects observed at the dose of 20 mg/eye.
The fluorescence detection of retinal cell apoptosis was also performed at 24 h after I/R (Fig. 4 D and E) . The retinal cell nuclei of the rats in the control group were essentially negative for TUNEL staining. TUNEL-positive cells, predominantly in the GCL and INL, were detected in the I/R-plus-vehicle group. Scattered TUNEL- positive cells were also observed in the ONL. By contrast, the percentage of TUNEL-positive cells was significantly decreased by 38.5% and 28% in the GCL and INL, respectively, in the I/R-plus-FK18 group.
To assess the protective effects of FK18 on RGCs, quantitative analysis of RGC survival was performed by the labeling of cells with FG at 7 d after I/R injury (Fig. 4 F and G) . The mean density of the FGlabeled RGCs was 1210 ± 117 RGC/mm 2 in the I/R-plus-vehicle group, representing 51% of the mean density of 2368 ± 211 RGC/ mm 2 observed in the control group. By contrast, a significant increase in the density of RGCs was detected in the I/R-plus-FK18 group (1504 ± 126 RGC/mm 2 ) compared with that in the vehicle group (p < 0.001).
ERG was recorded in all groups at 7 d after I/R injury (Fig. 4 H) . In the control group, the relative a-and b-wave ratio was approximately equal to 1. In the I/R-plus-vehicle group, retinal ischemia contributed to substantial decreases in the ratios (0.19 for a-wave; 0.20 for b-wave). By contrast, pretreatment with FK18 significantly improved the relative a-and b-wave ratios by 1.8-fold and 2.4-fold, respectively (Fig. 4 G and I) .
However, intravitreal administration of SCpep did not have protective effects against morphological and functional damage, apoptosis of the retina or loss of RGCs after I/R.
The effect of FK18 on phosphorylation of FGFR1 and Akt
As FK18 is derived from the active binding domain of bFGF, we then investigated the effect of FK18 on the phosphorylation of FGFR1, the primary receptor for bFGF. The result showed that treatment with FK18 resulted in a slight increase in FGFR1 phosphorylation after 10 min and 30 min, and this increase reached a peak at 1 h of incubation with FK18 (1.30-fold compared with that in the control group). After that, the phosphorylation gradually decreased but remained at a relatively high level (Fig. 5 A and D) .
To investigate the potential mechanisms underlying the protective effects of FK18, we examined p-Akt expression under both normoxic and OGD conditions by western blot analysis. Under normoxic conditions, a basal p-Akt level was observed, and treatment with FK18 increased this level in a time-dependent manner by 1.06-, 1.10-, 1.41-, 1.27-, and 1.24-fold compared with that in the control group after 10 min, 30 min, 1 h, 2 h and 4 h of treatment, respectively (Fig. 5 B and E) . Akt phosphorylation reached a peak at 1 h of incubation with FK18, after which it gradually decreased but remained at a relatively high level. Immediately after OGD, the p-Akt level was markedly decreased to 0.70 of the control level, while FK18 increased it to a near-normal level (1.13 of the control level) (Fig. 5 C and F) . In vivo, significantly increased expression of p-Akt was observed in FK18-treated rats. I/ R injury reduced the p-Akt level to 0.78 of the control level, while it significantly increased after the application of FK18 as shown in Fig. 5 H and I.
To determine whether the increased p-Akt contributes to the enhanced viability induced by FK18, we used a PI3K inhibitor, LY294002, to reduce the p-Akt level. As shown in Fig. 5 C, LY294002 blocked Akt phosphorylation both before and after OGD, resulting in p-Akt levels of 0.53 and 0.27 of the control level, respectively. In the presence of LY294002, FK18 was unable to increase the p-Akt level after OGD. Further, LY294002 abolished the neuroprotective effects of FK18, with a decrease in cell viability from 59.02± 3.66% to 49.68± 3.94% (Fig. 5 G) . LY294002 by itself did not reduce cell viability under normal conditions, although the basal p-Akt level was reduced (Fig. 5 C and G) . In addition, LY294002 did not enhance the reduced viability after OGD (Fig. 5  G) , suggesting that under normal conditions, other survival pathways may act in concert to compensate for the loss of Akt activity.
The effect of FK18 on the mitochondria-related apoptotic pathway in SH-SY5Y cells
Mitochondria play an important role in apoptosis by modulating the release of apoptotic factors from the mitochondria into the cytoplasm, which can result in activation of caspases and initiation of apoptotic events . After OGD injury, a significant amount of cytochrome c was released from the mitochondria into the cytoplasm (p < 0.01), whereas the addition of FK18 prevented the translocation of cytochrome c to the cytoplasm (p < 0.01). Proper subcellular fractionation without 1, 1, 10 , 50, and 100 mg/ml), SCpep (10 mg/ml) and recombinant human bFGF (100 ng/ml) 2 h prior to the induction of OGD for 6 h, followed by re-oxygenation for 12 h. The peak effect was observed with 10 mg/ml FK18, and it was selected to examine the protective effects in the following assays. The data are expressed as the mean ± SD. **p < 0.01 compared with the control group; # p < 0.05 and ## p < 0.01 compared with the OGD group. cross contamination was confirmed by the COX-IV expression patterns (Fig. 6 A, B and C) .
Both the phosphorylation of Bad (p-Bad) and the expression of Bcl-2 family proteins are involved in controlling the release of cytochrome c from the mitochondria into the cytoplasm. As shown in Fig. 6 , the p-Bad, Bcl-2 and Bcl-xL protein expression levels were significantly reduced after OGD injury, whereas they were significantly increased following the addition of FK18, and were further inhibited with the effect of LY294002 (Fig. 6 D to H) . In contrast, Bax expression was significantly up-regulated after injury, while it was down-regulated following the application of FK18, and was increased after the addition of LY294002 (Fig. 6 F) . The Bcl-2/Bax ratio was a sensitive determinant of the regulatory effects of OGD with or without FK18 and LY294002 pretreatment (OGD þ FK18, 1.07 ± 0.14, vs. OGD, 0.54 ± 0.14; OGD þ FK18 þ LY294002, 0.71 ± 0.08; Fig. 6 F and I) .
The relative protein expression levels of cleaved caspase-9 and cleaved caspase-3 were significantly increased after injury, whereas FK18 pretreatment suppressed these alterations (Fig. 6 J, K  and L) .
FK18 is non-toxic in vitro and in vivo
The potential toxicity of FK18 to SH-SY5Y cells in vitro was evaluated by MTS assay. The toxicity of intravitreal administration of FK18 was examined by biomicroscopy, transmission electron microscopy and ERG. In MTS assay, incubation of cells with different concentrations of FK18 for 24 h did not affect cell viability (Fig. 7 A) . Gross examination revealed no evidence of cataracts, vitreous hemorrhage, retinal detachment, or infection in any of the specimens after intravitreal injection of FK18 (20 mg/ eye) over a one-week observational period. Light microscopy demonstrated normal retinal morphology in the FK18-treated groups, with no edema, infiltration, or any other signs of inflammatory or immune reactions (Fig. 7 B) . Transmission electron microscopy did not reveal any obvious abnormalities of the different types of cells in the neuroretina, with no apparent swelling, vacuolization or disruption (Fig. 7 C, D and E ). There were no obvious changes in a-and b-wave morphology and amplitudes between baseline and one day and seven days after intravitreal injection of FK18 (Fig. 7 F) . 
Discussion
In the present study, we identified and characterized a novel 18-amino acid peptide, FK18, in the active binding domain of the conserved sequence of a potent neuroprotective protein, bFGF. We further established in vitro and in vivo models to assess the neuroprotective effects of FK18 and found that it effectively protected against ischemia-induced neuronal injury through the phosphorylation of Akt, the modulation of the mitochondria-related apoptotic pathway, and consequently, the attenuation of cell apoptosis.
OGD in the SH-SY5Y cell line has been used as a rapid and sensitive in vitro model of ischemic neuronal injury in the development of potential neuroprotective agents (Lin et al., 2011; Marutani et al., 2012) . We examined the viability of cells subjected to OGD for different durations by MTS assay and found that 6 h of OGD followed by 12 h of re-oxygenation resulted in the death of approximately 48% of the cells; thus, it was the most suitable condition for establishing stable ischemia in vitro. Pretreatment with FK18 significantly improved cell viability in a dose-dependent manner, and the concentration of 10 mg/ml was the most effective. Thus, duration of 6 h and concentration of 10 mg/ml were selected for use in the following experiments. It is widely accepted that the majority of ischemic neuronal cell death is due to apoptosis, which is a process of programmed cell death carried out by caspases (Choi, 1996; Elmore, 2007; Lam et al., 1999; Nijhawan et al., 2000) . Therefore, we further detected cell apoptosis by flow cytometry and TUNEL assay and caspase protein expression by western blotting. In this investigation, FK18 significantly attenuated the apoptosis of SH-SY5Y cells and inhibited the activation of caspase-9 and caspase-3 after OGD insult.
Retinal ischemia is a common condition and a relevant cause of visual impairment and blindness. The high IOP model of ocular ischemia in rats induced by transient elevation of IOP above ocular perfusion pressure is a well-recognized animal model used to study the effects of I/R injury and to evaluate potential neuroprotective agents (Osborne et al., 2004) . Consistent with previous studies (Chan et al., 2012; Zhang et al., 2012) , after 60 min of ischemia and 7 d of reperfusion, marked histologic degenerative changes and functional damage were detected in the retina, particularly in the inner retinal layers (Fig. 4 A) . However, intravitreal administration of FK18 significantly alleviated these morphological and functional changes in a dose-dependent manner. Further, FK18 significantly attenuated apoptosis in both the GCL and INL, as shown by TUNEL assay. RGCs are more susceptible to ischemia-induced injury compared with other retinal neurons (Jehle et al., 2008) , and the number of surviving RGCs is an important determinant of the protective effects of an agent. By labeling RGCs with FG, we showed that FK18 at least partly maintained the survival of RGCs at 7 d after injury, whereas a significant loss of RGCs was observed in the vehicle-treated rats. These animal results are consistent with those of the in vitro experiments, suggesting protective effects of FK18 against ischemia-induced neuronal damage through the attenuation of cell apoptosis. FGFR1 is the primary receptor for bFGF, and the activation of it leads to stimulation of intracellular signaling pathways that control cell proliferation, cell survival and etc. (Kiselyov et al., 2006; Plotnikov et al., 1999) . As FK18 is derived from the active binding domain of bFGF, we then tested the effect of FK18 on the phosphorylation of FGFR1. The results showed a time-dependent increase of phosphorylation of FGFR1 after incubation of FK18, which reached a peak at 1h. The Akt pathway is one of the downstream signaling pathways of FGFR1 (Eswarakumar et al., 2005; Wang et al., 2015) , and it has been established as an antiapoptotic pathway that is involved in cell survival and growth (Manning and Cantley, 2007) . Decreased Akt activity has been linked to the neuronal death induced by NMDA receptor activation, ischemia, or hypoxia, while increased Akt activity contributes to the neuroprotection induced by I/R in both the central nervous system and retina (Chen et al., 2015a; Corasaniti et al., 2007; Kokona and Thermos, 2015; Liu et al., 2010; Luo et al., 2003) . Akt is activated by PI3K via phosphorylation to generate its active form, p-Akt (Foster et al., 2003) . To further evaluate the biological mechanisms underlying the protective effects of FK18 on neurons, we examined activation of the Akt pathway in SH-SY5Y cells. We found that incubation of SH-SY5Y cells with FK18 resulted in the increased phosphorylation of Akt under normoxic conditions in a time-dependent manner, with peak phosphorylation observed at 1 h of incubation, after which the level remained relatively high. In addition, SH-SY5Y cells treated with OGD exhibited Akt dephosphorylation, which was counteracted by FK18. The FK18-mediated preservation of the p-Akt level contributed to the neuroprotection because inhibition of Akt activation with the PI3K inhibitor LY294002 blocked Akt phosphorylation and decreased cell viability. After Akt is activated, it phosphorylates targeted proteins involved in cell growth, metabolism and survival (Manning and Cantley, 2007) . Bad, a BH3 domain protein, is one of these targeted proteins. The phosphorylation of Bad at serine-136 by p-Akt allows for the sequestration of Bad in the cytoplasm (Datta et al., 1997 (Datta et al., , 2000 . Following cell stress, the loss of Akt activity leads to Bad dephosphorylation and its translocation to mitochondria, where it binds to the anti-apoptotic proteins Bcl-2/Bcl-xL (Yang et al., 1995) . This leads to the formation of homodimers of Bax, a proapoptotic member of the Bcl-2 family, and the subsequent release of cytochrome c into the cytoplasm to initiate the mitochondrial apoptotic pathway Oltvai et al., 1993) . Our data demonstrated that the dephosphorylation of Bad caused by OGD was partly prevented by pretreatment with FK18. Following Bad phosphorylation, Bcl-2/Bcl-xL was activated, while Bax was inactivated, and the release of cytochrome c from the mitochondria into the cytoplasm was inhibited. Collectively, our results suggest that FK18 might promote neuronal survival against ischemic injury by acting on FGFR1, and subsequently activating the Akt pathway and its downstream mitochondria-related apoptotic pathway (Fig. 8) . However, the interaction between FK18 and FGFR1, and the determination of exact acting site need further investigation.
We assessed the safety of FK18 by intravitreal administration to rats in vivo and incubation with SH-SY5Y cells in vitro. No notable retinal toxicity was detected over the one-week observational period, as evaluated by electrophysiological, micro-and ultrastructural examinations. In cell viability assay, no difference was observed between the FK18-treated SH-SY5Y cells (various concentrations) and control cells. All of these findings suggested a good tolerance of FK18 in neuroretina. Further specific toxicological studies should be performed before any clinical application.
A key finding in this study is that FK18 is a newly discovered peptide derived from bFGF. Although its neuroprotective activity is not superior to that of bFGF, its advantages with respect to ease of synthesis (chemical synthesis by solid-phase methods), viability for modifications in chemical synthesis, lower-antigenicity, and improved bioavailability over large proteins make it a potential alternative to recombinant proteins for use in neuroprotective therapy. There are also limitations to the present study. The solubility and half-life of natural peptide should be improved to better suit ocular application. The chemical modification and conjugation of FK18 and the development of a targeted drug release system would be helpful for overcoming these shortcomings and possibly increase the potency of FK18 to compete with bFGF. Multiple studies have shown that topically applied peptides can reach and are pharmacologically active in the posterior segment (Colafrancesco et al., 2011; Hernandez et al., 2013; Lambiase et al., 2005; Liu et al., 2012) . Thus, the pharmacokinetics and bioactivity of FK18 administered in eye drops should be assessed in future studies.
In conclusion, our results have demonstrated that FK18 has neuroprotective effects against ischemic insult both in vitro and in vivo possibly through activation of the Akt pathway and subsequent modulation of the mitochondria-related apoptotic pathway. These findings have indicated that FK18, a novel peptide derived from bFGF, might serve as a prototype for further development of neuroprotective drugs. Fig. 8 . Schematic mechanism of the neuroprotective effects of FK18 against OGD injury in SH-SY5Y cells. After acting on FGFR1, FK18 activates Akt by phosphorylating it at Ser437. In turn, Akt phosphorylates BAD at Ser136, leading to up-regulation of the antiapoptotic proteins Bcl-2/Bcl-xL and down-regulation of the pro-apoptotic protein Bax. These events attenuate the release of cytochrome c from the mitochondria into the cytoplasm, resulting in reduced caspase-9 and caspase-3 activities, eventually leading to a significant increase in neuronal survival.
